Markers of prodromal Alzheimer's disease

The diagnosis of Alzheimer's disease has long been considered a diagnosis of probability, as the definitive diagnosis can only be established by histopathological examination. However, the development of in-vivo biomarkers, considered a reflection of physiopathological processes, has changed ou...

Full description

Saved in:
Bibliographic Details
Published inRevue neurologique Vol. 168; no. 11; pp. 815 - 824
Main Authors de Souza, L C, Sarazin, M, Uspenskaya, O, Habert, M-O, Lamari, F, Lehéricy, S, Dubois, B
Format Journal Article
LanguageFrench
Published France 01.11.2012
Subjects
Alzheimer Disease - cerebrospinal fluid
Alzheimer Disease - diagnosis
Alzheimer Disease - pathology
Amyloid beta-Peptides - analysis
Amyloid beta-Peptides - cerebrospinal fluid
Biomarkers - analysis
Brain - diagnostic imaging
Diagnostic Imaging - methods
Early Diagnosis
Humans
Models, Biological
Prodromal Symptoms
Radiography
Radionuclide Imaging
tau Proteins - analysis
tau Proteins - cerebrospinal fluid
Online AccessGet full text

Cover

More Information
Summary:The diagnosis of Alzheimer's disease has long been considered a diagnosis of probability, as the definitive diagnosis can only be established by histopathological examination. However, the development of in-vivo biomarkers, considered a reflection of physiopathological processes, has changed our view of the disease. New criteria have recently been proposed that integrate such biomarkers as found in the cerebrospinal fluid (CSF) using new diagnostic tools such as magnetic resonance imaging (MRI), brain scintigraphy, FDG-positron emission tomography (PET) and PET amyloid ligand uptake studies. The value of these new criteria for the diagnosis of prodromal Alzheimer's disease and the prospect of disease-modifying drugs are also discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0035-3787
DOI:10.1016/j.neurol.2012.07.005